Edwards Lifesciences (EW, Financial) recently received an updated analyst rating from Evercore ISI Group. Analyst Vijay Kumar has decided to maintain an "In-Line" rating on the stock, indicating a consistent outlook on the company's performance.
In addition to maintaining the current rating, analyst Vijay Kumar has raised the price target for Edwards Lifesciences (EW, Financial) from the previous figure of $73.00 to the new target of $77.00. This represents a 5.48% increase in the price target, reflecting a more optimistic view on the company's future stock performance.
The updated price target and rating come amidst ongoing evaluations by analysts, providing investors with insights into potential developments for Edwards Lifesciences (EW, Financial). The decision to maintain the "In-Line" rating suggests a balanced perspective on the stock's growth prospects.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 27 analysts, the average target price for Edwards Lifesciences Corp (EW, Financial) is $81.28 with a high estimate of $95.00 and a low estimate of $61.00. The average target implies an upside of 5.98% from the current price of $76.69. More detailed estimate data can be found on the Edwards Lifesciences Corp (EW) Forecast page.
Based on the consensus recommendation from 32 brokerage firms, Edwards Lifesciences Corp's (EW, Financial) average brokerage recommendation is currently 2.4, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Edwards Lifesciences Corp (EW, Financial) in one year is $105.91, suggesting a upside of 38.1% from the current price of $76.69. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Edwards Lifesciences Corp (EW) Summary page.
